Moving forward we will continuously inform our respected shareholders about matters of importance.
2cureX AB (Ticker: 2CUREX) today announces continued momentum in its strategic execution, with the share price surging more than 1,000% over...
PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could a...
Protokoll från den ordinarie bolagsstämman 2024 for 2cureX AB (publ), torsdagen 26 juni 2025.
Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma torsdagen den 26 juni 2025 kl.
Årsredovisningen för 2024 för 2cureX AB (publ), 559128-0077, offentliggörs härmed.
2cureX AB has entered into an agreement with Mangold Fondkommission AB (“Mangold”) regarding the service as Certified Adviser.
2cureX AB (Ticker: 2CUREX) is proud to announce a historic commercial milestone: the company has successfully sold and initiated delivery of...
2cureX AB (Ticker: 2UREX), a leader in functional precision oncology, announces the initiation of an ambitious multi-phase commercial and cl...
The shareholders of 2cureX AB (publ) are hereby informed of the upcoming Annual General Meeting (AGM), which will take place on Thursday, Ju...
2cureX AB (“2cureX”) hereby publishes the interim report for the second half year of 2024.
2cureX has appointed Mangold Fondkommission AB (“Mangold”) as the Company’s liquidity provider.
2cureX has appointed Mangold Corporate Finance as the Company’s liquidity provider.
Nedan följer en sammanfattning av det beslut som fattades.
2cureX AB (Nasdaq First North: 2CUREX) proudly announces the appointment of Dan Honeywell as Chief Executive Officer, marking a significant ...
Aktieägarna i 2cureX AB, org. nr 559128-0077, ("Bolaget") kallas härmed till extra bolagsstämma onsdagen den 18 december 2024.
2cureX's Executive Management and Board of Directors are pleased to invite you to a webcast on 24 September 2024 at 20:00 CET.
The shareholders of 2cureX AB (publ) (“2cureX”), org.
2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2024.
Nedan följer en sammanfattning av de beslut som fattades.
Protokoll från den ordinarie bolagsstämman 2023 for 2cureX AB (publ), måndagen 1 juli 2024.
Årsredovisningen för 2023 för 2cureX AB (publ), 559128-0077, offentliggörs härmed.
Aktieägarna i 2cureX AB (publ) ("2cureX"), org.nr 559128-0077, kallas härmed till extra bolagsstämma.
2cureX AB (publ), a company pioneering the use of 3D tumoroids for drug sensitivity prediction in cancer patients, is pleased to announce th...
2cureX AB (publ) ("2cureX" or the "Company") today announces the intention to execute a directed issue of 7,500,000 shares at a Volume Weigh...
Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma måndagen den 1 juli 2024 kl.
2cureX AB has revised its financial calendar to align with its strategic shift and previously announced reductions in operational spending.
INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") announced on 16 March 2024 an update on the Compa...
INSIDE INFORMATION: The Board of Directors of 2cureX AB (publ) (the "Company" or "2cureX") has assessed that 2cureX has severe financial cha...
2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2023 and a financial and strategic outlook ...
Aktieägarna i 2cureX AB (publ) (”2Curex”), org.nr. 559128-0077, kallas härmed till extra bolagsstämma.
2cureX, a pioneer in the use of 3D tumoroids for predicting cancer treatment efficacy, is implementing significant changes in its governance...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces changes to managemen...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, is pleased to announce the app...
2cureX AB (“2cureX”) hereby publishes the interim report for the third quarter of 2023.
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the CE-Marking...
In connection with the Danish national fundraiser event – Knæk Cancer – the Danish Shareholders' Association arranged a panel discussion foc...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that it will focus a...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the signature ...
2cureX Management will present status on the published goals for 2023 and additional important achievements.
2cureX announced today the launch of two IVD products – IndiTreat® Specimen Collection Kit and IndiTreat® Shipping Container – that have bec...
2cureX AB (“2cureX”) hereby publishes the interim report for the second quarter of 2023.
2cureX will be holding its Q2 2023 online presentation with a Q&A session on July 12, 2023 at 20.
Idag, den 25 maj 2023, hölls årsstämma i 2cureX AB.
2cureX AB (“2cureX”) hereby publishes the interim report for the first quarter of 2023.
University Hospital of Southern Denmark has had the positive IndiTreat® trial results published in the highly recognized “Journal of Experim...
Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma torsdagen den 25 maj 2023 kl.
Fernando Andreu, CEO at 2cureX announces the purchase of 18.
Copenhagen — April 20, 2023 — Styrelsen och verkställande direktören för 2cureX AB (”2cureX”) offentliggör härmed årsredovisning för räkensk...
2cureX will today, at a Q&A session, present commercial results for Q1 2023 and other important achievements in this quarter.
2cureX announced today that it has been awarded a grant of 1.
2cureX will have its Q1 2023 online presentation with a Q&A session on April 12, 2023 at 20.
2cureX announced today that the company has, together with its technology partners, Hahn-Schickard Institute and the Department of Microsyst...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the launch of ...
2cureX AB (“2cureX”) hereby publishes the interim report for the fourth quarter and full year of 2022.
2cureX will publish its Year-End/Q4 2022 report on Thursday, February 23, at 08:30 CET.
Idag, den 10 februari 2023, hölls extra bolagsstämma i 2cureX AB.
Januari 23 2023
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the final resu...
2cureX AB (“2cureX”) hereby publishes the interim report for the third quarter and first nine months of 2022.
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will publish its Q3 2022 repor...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, will hold a Strategy Deep-Dive...
Market developments and strategic progress in functional drug sensitivity testing
2cureX has commissioned independent market research experts 2HMforum to survey GI oncologists as to their ‘Attitude towards drug sensitivity...
Professor Morten Meldal was yesterday awarded the Nobel Prize in Chemistry.
2cureX terminates liquidity provision service
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has ch...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, today announced the signature ...
2cureX AB (”2cureX”) offentliggör härmed delårsrapport för det andra kvartalet och första halvåret 2022.
Extra bolagsstämman i 2cureX AB ("2cureX" eller "Bolaget") hölls idag den 8 augusti 2022 varvid aktieägarna fattade följande beslut.
Aktieägarna i 2cureX AB, org. nr 559128-0077, ("Bolaget") kallas härmed till extra bolagsstämma måndagen den 8 augusti 2022.
2cureX, a company pioneering the use of 3D micro-tumors (tumoroids) for drug sensitivity testing in patients with cancer, announced today th...
2cureX, a IVD Diagnostic company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announces that ...
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has re...
Idag, den 24 maj 2022, hölls årsstämma i 2cureX AB.
2cureX AB (”2cureX”) offentliggör härmed delårsrapport för det första kvartalet 2022.
2cureX will publish its Q1 2022 interim report on Tuesday, 24 May 2022 at 12:00 CET.
Three IndiTreat® posters have been accepted at the World Congress on Gastrointestinal Cancer, hosted in Barcelona by the European Society fo...
Dr. Michael Schaefer har föreslagits som ny styrelseledamot i 2cureX AB.
The enrollment of hospitals in the IGNITE program - 2cureX initiative to speed up the adoption of IndiTreat® - is progressing as planned.
2cureX is pioneering drug sensitivity testing for the individualized selection of cancer treatment.
2cureX har utsett Sedermera Corporate Finance till bolagets likviditetsgarant.
After the publication of the Annual Report 2021, Redeye’s Equity Research Analyst Eric Nordström interviews 2cureX CEO Fernando Andreu about...
Copenhagen — May 3, 2022 — Styrelsen och verkställande direktören för 2cureX AB (”2cureX”) offentliggör härmed årsredovisning för räkenskaps...
Rättelser har gjorts av “Aktieägare som önskar delta i årsstämman ska” ändras från den 17 maj till 16 maj och “Förvaltarregistrerade aktier”...
Aktieägarna i 2cureX AB (publ), 559128-0077, kallas härmed till årsstämma tisdagen den 24 maj 2022 kl.
2cureX, a company pioneering the use of 3D micro-tumors (tumoroids) for drug sensitivity testing in patients with cancer, announced today a ...
2cureX AB (“2cureX”) hereby announces that the Chairman of the 2cureX Board Povl-Andre’ Bendz has chosen to use his rights to subscribe for ...
